Diabetes
That 'healthy' juice habit? It might be messing with your metabolism
Think juice is better than soda? A large new study shows even 100% fruit juice raises diabetes risk, urging people to eat whole fruits instead
Obesity injections may have less weight loss effect in reality: Study
Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study in US patients has found. Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide (Zepbound and Mounjaro) are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar. The study, published in the Obesity Journal, examined the effects of anti-obesity injectables on weight reduction and blood sugar regulation (glycaemic control) in a real-world setting. "Our study shows that patients treated for obesity with semaglutide or tirzepatide lost less weight on average in a regular clinical setting compared to what is observed in randomised clinical trials," lead author Dr Hamlet Gasoyan, a researcher with the Cleveland Clinic, US, said. "According to our data, this could be explained by higher rates of discontinuation and lower
Eli Lilly's weight loss drug Mounjaro sales bulk up 60% on dosage upgrade
It logged value sales worth Rs 12.61 crore in May, compared to Rs 7.88 crore in April.
Lilly's obesity drug Mounjaro's sales rise 60% in India amid rising demand
The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies
Biocon gets CDSCO approval for generic diabetes medication 'Liraglutide'
Biotech firm Biocon on Tuesday said it has received approval from the government authorities for a generic diabetes medication. The company has received approval for its Liraglutide drug substance and its wholly-owned subsidiary Biocon Pharma has received approval for its Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge), from the Drugs Controller General of India (CDSCO). The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise, the company said in a regulatory filing. "The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes," Biocon CEO and MD Siddharth Mittal said. India has one of the highest number of people with diabetes globally, with ...
Novo Nordisk to launch weight-loss drug Wegovy in India ahead of schedule
Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in the Indian market
Can the '2 per 20' rule really help stabilise blood sugar without exercise?
Research shows that light walking for 2 minutes after every 20 minutes of sitting may significantly lower post-meal blood sugar levels
5 products to be launched in 18 mths, US insulin mkt share up: BBL MD & CEO
Achieving 15 per cent year-on-year growth, with nearly four biosimilars with $200 million in revenue, is a big feat, says Tambe
Insulin's century-old legacy still stands tall amid new diabetes drugs
Despite the rise of GLP-1s and oral therapies, insulin remains vital for millions, particularly those with type 1 diabetes and other insulin-dependent conditions
Patent loss led to rise in prescriptions of new generation diabetes drugs
Experts say 85% price drop in empagliflozin expected to boost SGLT2 usage; SGLT-2 class of drugs account for 25-30% of all diabetes prescriptions
What is Type 5 diabetes? IDF recognises malnutrition-linked condition
Long overlooked and often misdiagnosed, Type 5 diabetes, caused by malnutrition-linked reduced insulin production, has finally gained official recognition
Hit the gym! Building muscles may cut diabetes risk by 44%, genes no bar
Muscle up, sugar down: A new study has found individuals with high muscle strength have a 44% lower risk of developing type 2 diabetes, irrespective of their genetic predisposition to the disease
Eli Lilly launches blockbuster anti-obesity drug Mounjaro in India. Prices here
Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what you need to know
Glenmark launches Empagliflozin for diabetes in India under Glempa brand
Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes patients. The Mumbai-based drug firm has launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'?Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk. Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, supporting weight-loss, and reducing cardiovascular-renal risks in patients with type 2 diabetes mellitus. Empagliflozin has also demonstrated benefits in heart failure patients by lowering the cardiovascular death or hospitalisation. "The launch of Glempa range ..
Biocon launches drug Liraglutide for diabetes, Biolide for obesity in UK
Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK. The GLP-1 peptide, Liraglutide, will be marketed in the UK under the brand names Liraglutide Biocon for diabetes and Biolide for chronic weight management, the company said in a statement. The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, earlier this year, making Biocon Ltd the first generics company to obtain approval for gLiraglutide in a major regulated market, it added. "The timely launch will offer healthcare providers and patients affordable access to this drug and help fulfil an unmet need," Biocon CEO and MD Siddharth Mittal said. The company will continue to focus its efforts towards expanding the reach of gLiraglutide into other European markets, the US and select geographies, he added. Glucagon-like peptide-1 (GLP-1) are medications that help lower blood sugar levels and promote weight loss. Liraglutid
Asian healthcare market to touch $5 trillion by 2030, says BCG report
Asia accounts for 22 per cent of global healthcare spending despite being home to 60 per cent of the global population
Lupin acquires Huminsulin from Lilly to strengthen diabetes portfolio
The Huminsulin range is vital for managing both type 1 and type 2 diabetes, helping control blood sugar levels in adults and children
88 mn women screened for cervical cancer under national programme: Govt
Over 8.8 crore women have been screened for cervical cancer under the National Programme for Prevention and Control of Non-Communicable Disease of which nearly 98,000 were diagnosed with the disease, Union Health Minister J P Nadda told the Rajya Sabha on Tuesday. Under the same programme, over 14 crore were screened for breast cancer and more than 26 crore for oral cancer. Among them, nearly 56,000 breast cancer cases and 1.56 lakh oral cancer cases were detected, he said. Besides, 32.52 crore people were screened for hypertension and 32.36 crore for Diabetes. The number of diagnosed cases were 3.21 crore and 2.05 crore respectively. In order to prevent and control major non-communicable diseases (NCDs) including stroke cases, the National Programme for Prevention and Control of Non-Communicable Disease (NP-NCD) was launched by the Department of Health and Family Welfare, Government of India, in 2010. It focuses on strengthening infrastructure, human resource development, health .
ICMR sets up India's first diabetes biobank in Chennai for research
The country's first diabetes biobank, a repository of population-based biological samples aimed at supporting scientific research, has been established in Chennai by the Indian Council of Medical Research (ICMR) in collaboration with the Madras Diabetes Research Foundation (MDRF). The biobank set up at the MDRF, Chennai aims to gather, process, store and distribute biospecimens to assist scientific studies with the permission of the ICMR. The biobank will facilitate advanced research on the causes of diabetes, the variations of the Indian type of diabetes and related disorders, said Dr V Mohan, chairman of the MDRF and Dr Mohan's Diabetes Specialities Centre. The biobank has blood samples from two ICMR-funded studies -- the ICMR-?India Diabetes (ICMR-?INDIAB) study conducted in all states and Union territories in phases from 2008 to 2020 and the "Registry of people with diabetes in India at a young age at the onset", which was launched in 2006 and is still ongoing. A plethora of bl
